{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:39:45Z","timestamp":1794109185440,"version":"4.8.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.lungcan.2023.107281","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T08:31:01Z","timestamp":1687336261000},"page":"107281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-6563","authenticated-orcid":false,"given":"Michael","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md","family":"Ashfaq Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Sook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Scorsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison C.","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Slotman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107281_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2022.100361","article-title":"The case for SABR as the global standard for non-operable early-stage non-small cell lung cancer","volume":"14","author":"Mutsaers","year":"2022","journal-title":"Lancet Regional Health - Americas"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107281_b0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107281_b0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2021.07.007","article-title":"Stereotactic ablative radiotherapy in T1\u20132N0M0 small cell lung cancer: a systematic review and meta-analysis","volume":"160","author":"Safavi","year":"2021","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0020","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2023.107281_b0025","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy Vs. Maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"10185","key":"10.1016\/j.lungcan.2023.107281_b0030","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lungcan.2023.107281_b0035","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/cncr.31196","article-title":"Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: a comprehensive review","volume":"124","author":"Tandberg","year":"2018","journal-title":"Cancer"},{"issue":"30","key":"10.1016\/j.lungcan.2023.107281_b0040","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.lungcan.2023.107281_b0045","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107281_b0050","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.jtho.2021.04.002","article-title":"Stereotactic radiation for lung cancer: a practical approach to challenging scenarios","volume":"16","author":"Andruska","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107281_b0055","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: a systematic review","volume":"14","author":"Chen","year":"2019","journal-title":"J. Thoracic Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107281_b0060","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","article-title":"The HILUS-trial\u2014a prospective nordic multicenter phase 2 study of ultracentral lung tumors treated with stereotactic body radiotherapy","volume":"16","author":"Lindberg","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107281_b0065","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijrobp.2021.10.143","article-title":"Performing SBRT in the fly-with-caution zone: are we heeding the advice of daedalus?","volume":"112","author":"Swaminath","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"10","key":"10.1016\/j.lungcan.2023.107281_b0070","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"15","key":"10.1016\/j.lungcan.2023.107281_b0075","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology A proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2023.107281_b0080","unstructured":"Wells GA SB, D. O\u2019Connell, J. Peterson, V. Welch, M. Losos, et al. The Newcastle-Ottawa Scale (NOS) for assessing thequality if nonrandomized studies in meta-analyses. https:\/\/www.ohri.ca\/\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"10.1016\/j.lungcan.2023.107281_b0085","unstructured":"WebPlotDigitizer. Version 4.2. 2019. https:\/\/automeris.io\/WebPlotDigitizer."},{"key":"10.1016\/j.lungcan.2023.107281_b0090","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 (The National Cancer Institute) (2017)."},{"key":"10.1016\/j.lungcan.2023.107281_b0095","unstructured":"Common Terminology Criteria for Adverse Events version 4 (National Cancer Institute) (2010)."},{"issue":"7129","key":"10.1016\/j.lungcan.2023.107281_b0100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.316.7129.469","article-title":"Bias in meta-analysis detected by a simple, graphical","volume":"316","author":"Stuck","year":"1998","journal-title":"BMJ"},{"issue":"7414","key":"10.1016\/j.lungcan.2023.107281_b0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107281_b0110","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/j.ijrobp.2021.07.1211","article-title":"Analysis of toxicity and local control for ultra-central lung tumors undergoing stereotactic body radiation therapy","volume":"111","author":"Sidiqi","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107281_b0115","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract. Radiat. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107281_b0120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.radonc.2018.07.001","article-title":"The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors","volume":"129","author":"Chang","year":"2018","journal-title":"Radiother. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0125","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-018-1017-y","article-title":"Stereotactic body radiotherapy for central lung tumors, yes we can!","volume":"13","author":"Korzets ceder","year":"2018","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.lungcan.2023.107281_b0130","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.radonc.2019.01.035","article-title":"Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours","volume":"134","author":"Lenglet","year":"2019","journal-title":"Radiother. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107281_b0135","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1080\/0284186X.2021.1942545","article-title":"Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy","volume":"60","author":"Lodeweges","year":"2021","journal-title":"Acta Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107281_b0140","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jtho.2016.03.008","article-title":"Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with \u201cultracentral\u201d non-small cell lung cancer","volume":"11","author":"Tekatli","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0145","doi-asserted-by":"crossref","DOI":"10.1186\/1756-8722-3-39","article-title":"CyberKnife for hilar lung tumors: report of clinical response and toxicity","volume":"3","author":"Unger","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lungcan.2023.107281_b0150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2020.07.009","article-title":"Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors","volume":"147","author":"Wang","year":"2020","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0155","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-016-0608-8","article-title":"Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases","volume":"11","author":"Lischalk","year":"2016","journal-title":"Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107281_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2020.11.003","article-title":"Safety and Efficacy of stereotactic body radiotherapy in ultracentral lung tumors using a risk-optimized fractionation scheme","volume":"22","author":"Regnery","year":"2021","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2008.12.016","article-title":"Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus","volume":"66","author":"Song","year":"2009","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2023.107281_b0170","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.clon.2021.05.005","article-title":"Late toxicity and long-term local control in patients with ultra-central lung tumours treated by intensity-modulated radiotherapy-based stereotactic ablative body radiotherapy with homogenous dose prescription","volume":"33","author":"Mihai","year":"2021","journal-title":"Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107281_b0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/09553002.2019.1552375","article-title":"Is stereotactic body radiotherapy for ultra-central lung tumor a feasible option? A systemic review and meta-analysis","volume":"95","author":"Rim","year":"2019","journal-title":"Int. J. Radiat Biol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107281_b0180","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.21037\/tlcr-20-503","article-title":"Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis","volume":"9","author":"Rim","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107281_b0185","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107281_b0190","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107281_b0195","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.radonc.2015.09.008","article-title":"Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy","volume":"118","author":"Guckenberger","year":"2016","journal-title":"Radiother. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107281_b0200","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107281_b0205","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijrobp.2022.08.028","article-title":"Stereotactic body radiation therapy for lung metastases from sarcoma in oligometastatic patients: a phase 2 study","volume":"114","author":"Navarria","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijrobp.2018.08.040","article-title":"Subgroup survival analysis in stage I-II NSCLC patients with a central tumor partly treated with risk-adapted SBRT","volume":"103","author":"Stam","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0215","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.lungcan.2015.04.014","article-title":"Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors","volume":"89","author":"Chaudhuri","year":"2015","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2023.107281_b0220","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.ijrobp.2018.10.008","article-title":"Stereotactic radiation for ultra-central lung tumors: good idea, or ultra-risky?","volume":"103","author":"Palma","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0225","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2020.01.009","article-title":"Validation of RTOG 0813 proximal bronchial tree constraints for pulmonary toxicity with stereotactic body radiation therapy for central non-small cell lung cancer","volume":"107","author":"Manyam","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107281_b0230","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: Stereotactic radiation for ultracentral non-small-cell lung cancer-A safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107281_b0235","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0360-3016(97)00008-4","article-title":"Does additional brachytherapy improve the effect of external irradiation? A prospective, randomized study in central lung tumors","volume":"38","author":"Huber","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0240","doi-asserted-by":"crossref","DOI":"10.1177\/0300060519896919","article-title":"Do lung cancer patients require routine anticoagulation treatment? A meta-analysis","volume":"48","author":"Zhang","year":"2020","journal-title":"J. Int. Med. Res."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107281_b0245","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijrobp.2015.02.016","article-title":"Gastrointestinal Toxicities with combined antiangiogenic and stereotactic body radiation therapy","volume":"92","author":"Pollom","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0250","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijrobp.2013.05.012","article-title":"Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT)","volume":"87","author":"Barney","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107281_b0255","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jamaoncol.2019.0205","article-title":"Analysis of toxic effects with antiangiogenic agents plus stereotactic body radiation in ultracentral lung tumors.","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107281_b0260","article-title":"Safety and tolerability of metastasis-directed radiation therapy in the era of evolving systemic, immune, and targeted therapies","volume":"7","author":"Guimond","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107281_b0265","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC\u2013ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107281_b0270","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jtho.2020.02.005","article-title":"A primer on interstitial lung disease and thoracic radiation","volume":"15","author":"Goodman","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1051","key":"10.1016\/j.lungcan.2023.107281_b0275","doi-asserted-by":"crossref","first-page":"20150036","DOI":"10.1259\/bjr.20150036","article-title":"LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective","volume":"88","author":"Adebahr","year":"2015","journal-title":"Br. J. Radiol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0280","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.adro.2018.10.003","article-title":"Stereotactic MR-guided online adaptive radiation therapy (SMART) for ultracentral thorax malignancies: results of a phase 1 trial","volume":"4","author":"Henke","year":"2019","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.lungcan.2023.107281_b0285","article-title":"Advances in proton therapy in lung cancer","volume":"12","author":"Vyfhuis","year":"2018","journal-title":"Therapeutic Adv. Respiratory Dis."},{"key":"10.1016\/j.lungcan.2023.107281_b0290","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.radonc.2021.03.001","article-title":"Ablative radiotherapy for ultracentral lung cancers: dosimetric, geometric, and volumetric predictors of outcomes and toxicity","volume":"158","author":"Breen","year":"2021","journal-title":"Radiother. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2023.107281_b0295","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/1759-7714.13105","article-title":"Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer","volume":"10","author":"Cong","year":"2019","journal-title":"Thoracic Cancer"},{"key":"10.1016\/j.lungcan.2023.107281_b0300","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tipsro.2020.01.002","article-title":"Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: initial outcomes","volume":"13","author":"Cooke","year":"2020","journal-title":"Techn. Innov. Patient Support Radiat. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2023.107281_b0305","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.3390\/cancers13143463","article-title":"Exceeding radiation dose to volume parameters for the proximal airways with stereotactic body radiation therapy is more likely for ultracentral lung tumors and associated with worse outcome","volume":"13","author":"Farrugia","year":"2021","journal-title":"Cancers"},{"issue":"1129","key":"10.1016\/j.lungcan.2023.107281_b0310","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210533","article-title":"Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience","volume":"95","author":"Guillaume","year":"2022","journal-title":"Br. J. Radiol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107281_b0315","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00066-020-01687-9","article-title":"Dose coverage impacts local control in ultra-central lung oligometastases treated with stereotactic radiotherapy","volume":"197","author":"Loi","year":"2021","journal-title":"Strahlenther. Onkol."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107281_b0320","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1111\/cas.14185","article-title":"Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer","volume":"110","author":"Meng","year":"2019","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107281_b0325","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.prro.2018.11.005","article-title":"Tumor control and toxicity after SBRT for ultracentral, central, and paramediastinal lung tumors","volume":"9","author":"Nguyen","year":"2019","journal-title":"Pract. Radiat. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107281_b0330","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/09553002.2019.1626026","article-title":"A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor","volume":"95","author":"Park","year":"2019","journal-title":"Int. J. Radiat. Biol."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107281_b0335","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1016\/j.cllc.2018.06.001","article-title":"Ultracentral tumors treated with stereotactic body radiotherapy: single-institution experience","volume":"19","author":"Raman","year":"2018","journal-title":"Clin. Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107281_b0340","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/1759-7714.13335","article-title":"Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Thoracic Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107281_b0345","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-020-01491-w","article-title":"Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors","volume":"15","author":"Zhao","year":"2020","journal-title":"Radiat. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300819X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300819X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:05:40Z","timestamp":1759237540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022300819X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":69,"alternative-id":["S016950022300819X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107281","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107281"}}